79 related articles for article (PubMed ID: 21118641)
21. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
[TBL] [Abstract][Full Text] [Related]
23. [Expression and clinical significance of p53 protein , estrogen and progesterone receptors in non-small cell lung cancer].
Zhang H; Lu F; Deng L; Wang S; Yan H
Zhongguo Fei Ai Za Zhi; 2000 Aug; 3(4):276-9. PubMed ID: 20955676
[TBL] [Abstract][Full Text] [Related]
24. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
Tsai MF; Wang CC; Chang GC; Chen CY; Chen HY; Cheng CL; Yang YP; Wu CY; Shih FY; Liu CC; Lin HP; Jou YS; Lin SC; Lin CW; Chen WJ; Chan WK; Chen JJ; Yang PC
J Natl Cancer Inst; 2006 Jun; 98(12):825-38. PubMed ID: 16788156
[TBL] [Abstract][Full Text] [Related]
25. [Study on the relationship among multidrug resistance factor expression of lung cancer tissues and clinicopathological characteristics in patients with lung cancer].
Zhang L; Yang H; Dong D
Zhongguo Fei Ai Za Zhi; 2006 Feb; 9(1):60-4. PubMed ID: 21144284
[TBL] [Abstract][Full Text] [Related]
26. [Expression of integrin-linked kinase and E-cadherin in non-small cell lung cancer].
Shi R; Zhang D; Fang X; Yu J; Qiu X; Wang E
Zhongguo Fei Ai Za Zhi; 2005 Aug; 8(4):291-6. PubMed ID: 21108884
[TBL] [Abstract][Full Text] [Related]
27. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
28. Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer.
Porebska I; Wyrodek E; Kosacka M; Adamiak J; Jankowska R; Harłozińska-Szmyrka A
In Vivo; 2006; 20(5):599-604. PubMed ID: 17091766
[TBL] [Abstract][Full Text] [Related]
29. p16INK4a expression and clinicopathologic parameters in renal cell carcinoma.
Ikuerowo SO; Kuczyk MA; von Wasielewski R; Shittu OB; Jonas U; Machtens S; Serth J
Eur Urol; 2007 Mar; 51(3):732-7; discussion 738. PubMed ID: 16949731
[TBL] [Abstract][Full Text] [Related]
30. Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication.
Shimamoto T; Ohyashiki JH; Hirano T; Kato H; Ohyashiki K
Oncol Rep; 2004 Aug; 12(2):389-95. PubMed ID: 15254707
[TBL] [Abstract][Full Text] [Related]
31. [Expression of KAI1 gene in non-small cell lung cancer and its relationship with P53].
Guo C; Pan T; Tang Y; Zhou Y; Zheng Z
Zhongguo Fei Ai Za Zhi; 2005 Jun; 8(3):190-4. PubMed ID: 21190617
[TBL] [Abstract][Full Text] [Related]
32. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
33. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
[TBL] [Abstract][Full Text] [Related]
34. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer.
Iwata T; Uramoto H; Sugio K; Fujino Y; Oyama T; Nakata S; Ono K; Morita M; Yasumoto K
Lung Cancer; 2005 Oct; 50(1):67-73. PubMed ID: 15950316
[TBL] [Abstract][Full Text] [Related]
35. Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival.
Laudanski J; Chyczewski L; Niklińska WE; Kretowska M; Furman M; Sawicki B; Nikliński J
Neoplasma; 1999; 46(1):25-30. PubMed ID: 10355530
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53.
Hirabayashi H; Ohta M; Tanaka H; Sakaguchi M; Fujii Y; Miyoshi S; Matsuda H
J Surg Oncol; 2002 Dec; 81(4):177-84; discussion 184. PubMed ID: 12451621
[TBL] [Abstract][Full Text] [Related]
37. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC).
Liu YZ; Jiang YY; Hao JJ; Lu SS; Zhang TT; Shang L; Cao J; Song X; Wang BS; Cai Y; Zhan QM; Wang MR
Lung Cancer; 2012 Jul; 77(1):176-82. PubMed ID: 22456526
[TBL] [Abstract][Full Text] [Related]
39. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.
Wu WG; Soria JC; Wang L; Kemp BL; Mao L
Anticancer Res; 2000; 20(6B):4525-9. PubMed ID: 11205299
[TBL] [Abstract][Full Text] [Related]
40. [Expression of PTEN, p53 and P-glycoprotein in Non-small cell Lung Cancer and Their Predictive Values.].
Zhang H; Shu H; Jiang W
Zhongguo Fei Ai Za Zhi; 2009 Nov; 12(11):1213-6. PubMed ID: 20723372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
